Anti-CD19 chimeric antigen receptor T cell therapy - Intrexon/ZIOPHARM

Drug Profile

Anti-CD19 chimeric antigen receptor T cell therapy - Intrexon/ZIOPHARM

Latest Information Update: 10 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Intrexon Corporation; ZIOPHARM Oncology
  • Developer Intrexon Corporation; National Cancer Institute (USA); University of Texas M. D. Anderson Cancer Center; ZIOPHARM Oncology
  • Class Antineoplastics; CAR-T cell therapies
  • Mechanism of Action Apoptosis stimulants; Gene expression modulators; Gene transference; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I B cell lymphoma; Leukaemia
  • Preclinical Multiple myeloma

Most Recent Events

  • 06 Nov 2017 Anti-CD19 chimeric antigen receptor T-cell therapy is still in phase I trials for B-cell lymphoma (In adults, In the elderly, Late-stage disease, Refractory metastatic disease) and Leukaemia (In children, Late-stage disease, Refractory metastatic disease, Second-line therapy or greater) in USA
  • 31 Jan 2017 Pharmacodynamics data from a preclinical study in Cancer released by ZIOPHARM Oncology
  • 31 Jan 2017 ZIOPHARM Oncology plans a phase I trial of third-generation anti-CD19 CAR T-cell therapy for Cancer in 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top